Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05516316
Other study ID # EP395-002
Secondary ID 2021-005867-28
Status Completed
Phase Phase 1
First received
Last updated
Start date October 11, 2022
Est. completion date June 21, 2023

Study information

Verified date June 2023
Source EpiEndo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the effect of EP395 against an induced inflammation of the lung. In addition, further data about the safety and tolerability of EP395 will be collected. To investigate the efficacy of EP395 at the end of the treatment with EP395 or placebo (dummy), all participants will inhale a lipopolysaccharide (a molecule composed of sugar and fat) that artificially induces an acute inflammation of the airways. It is assumed that participants who received EP395 will show less inflammation of the airways than participants who received placebo.


Description:

This is a study to assess the pharmacological effect of repeated doses of EP395 in healthy subjects with the aim to assess the effects of EP395 on lung and blood markers of inflammation after inhaled lipopolysaccharide (LPS), and the safety, tolerability, and systemic exposure of EP395. The study will be randomised in a 1:1 ratio to take either high dose EP395 or placebo as oral capsules once daily for 21 days starting on Day 1 with scheduled visits at Days 7, 14, and 21 for assessments of safety and tolerability and systemic exposure of EP395. At Day 21, 2 hours after the last investigational product (IP) intake, participants will undergo an inhaled LPS challenge to induce airway inflammation, which will be followed by bronchoscopy and BAL 6 hours later. A final safety follow-up visit will be performed at Day 37. If the data from the high dose EP395 arm (variability, effect size) indicate that it may be possible to detect effects on IL-8 at a lower dose of EP395, an additional lower dose EP395 arm will be added.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date June 21, 2023
Est. primary completion date June 21, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility 1. Willing and able to understand the information on the nature, the scope and the relevance of the clinical study, and to provide voluntary, written informed consent to participate in the study before any study-related procedures 2. Men and women, aged =18 and =55 years 3. Women of childbearing potential must: 1. have a negative pregnancy test (blood) at Screening. 2. agree to use, and be able to comply with, highly effective measures of contraceptive control (failure rate less than 1% per year when used consistently and correctly) without interruption, from Screening until 90 days after the last IP intake. 4. Men must agree to use contraception (barrier method) during sexual intercourse with women of childbearing potential during treatment until 90 days after the last IP intake and should not donate sperm during this time. 5. In good health as determined by medical history and screening investigations, as judged by the investigator 6. Body mass index of =19 and =33 kg/m2 7. Normal spirometry (forced expiratory volume in 1 second [FEV1] >80% predicted and FEV1/forced vital capacity >70%) 8. Non-smoker or former smoker with <10 pack years who had stopped smoking (including e-cigarettes) for at least 6 months before Screening. Exclusion Criteria: 1. History or presence of any clinically relevant medical condition that could affect the participant's safety or interfere with the objectives of the study 2. Presence or history of lung disease, eg, asthma, chronic obstructive pulmonary disease 3. Clinically significant abnormality on 12-lead ECG including prolonged corrected QT interval by Fredericia (>450 msec men or >470 msec women) 4. Use of prescribed or nonprescribed medications or herbal remedies within 28 days of first dosing and during the study with the exception of 1. hormone replacement therapy (HRT) 2. contraception 3. occasional use of paracetamol 5. Positive hepatitis B surface antigen, hepatitis C antibodies, HIV-1 or -2 antibodies 6. Positive drugs of abuse, smoking, or alcohol test at Screening 7. History of alcohol or drug misuse 8. Pregnant and lactating women 9. Prior recovery from recent infection, including but not limited to COVID-19, within the last 14 days before first dosing with IP 10. History of hypersensitivity to any constituents of the IMP or LPS 11. Any clinically significant allergy 12. Participation in a clinical study with an IP within 3 months or 5 half-lives before first dosing, whichever is longer 13. Employees of the sponsor or employees or relatives of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EP395
Capsule for oral use
Placebo
Capsule for oral use

Locations

Country Name City State
Germany Fraunhofer Institute for Toxicology and Experimental Medicine ITEM Hannover

Sponsors (2)

Lead Sponsor Collaborator
EpiEndo Pharmaceuticals FGK Clinical Research GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bronchoalveolar lavage fluid interleukin 8 at Day 21 Day 21
Secondary ECG ventricular rate Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary ECG RR interval Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary ECG PR interval Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary ECG QRS duration Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary ECG QT interval (uncorrected) Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary ECG QTcF intervals Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary Assessment of laboratory values (haematology) Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary Assessment of laboratory values (blood biochemistry) Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary Assessment of blood coagulation Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary Urinalysis Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days), Day 37 (±3 days)
Secondary Vital signs: Systolic and diastolic blood pressure Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days)
Secondary Vital signs: Pulse Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days)
Secondary Vital signs: Body temperature Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -21 to Day -1), Days 1, 7 (±2 days), 14 (±2 days), Day 21 (±2 days)
Secondary Height and weight BMI will be calculated from height and weight measurements Screening (Day -21 to Day -1), Day 37 (±3 days)
Secondary Standard routine physical examination A standard routine physical body examination will be performed and abnormal physical examination results will be evaluated and reported as AEs. Screening (Day -21 to Day -1), Days 1, Day 21 (±2 days), Day 37 (±3 days)
Secondary Assessment of adverse event (AE) occurrence From Screening (Day -21 to Day -1), to Day 37 (±3 days)
Secondary BALF cell count (total and differential) and mediators Including tumour necrosis factor (TNF)-a, IL-6, IL-1ß, macrophage inflammatory protein (MIP)-1a, MIP-1ß, monocyte chemotactic protein-1, intercellular adhesion molecule-1, surfactant protein (SP)-D, granulocyte macrophage colony-stimulating factor, IL-23, IL-33, IL-25, IL-10, albumin, and protein Day 21 (±2 days)
Secondary Exhaled particles IL-6 and IL-8 Day 21 (±2 days)
Secondary Blood inflammatory markers including C-reactive protein, TNF-a, IL-6, IL-8, and a2-macroglobulin Day 21 (±2 days)
Secondary Plasma EP395 Day 7 (±2 days) [only applicable for trough levels of EP395], Day 14 (±2 days) and Day 21 (±2 days)
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy